Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 116,071 shares of CYTK, which is worth approximately $5.83 Million. The most recent transaction as insider was on Feb 18, 2025, when has been sold 2,000 shares (Common Stock) at a price of $45.98 per share, resulting in proceeds of $91,960. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 116K

1.93% 3M change

18.82% 12M change

Total Value Held $5.83 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	SELL Open market or private sale	$91,960 $45.98 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Feb 18 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Feb 04 2025	SELL Open market or private sale	$96,120 $48.06 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Feb 04 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Jan 21 2025	SELL Open market or private sale	$91,840 $45.92 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Jan 21 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Jan 07 2025	SELL Open market or private sale	$98,640 $49.32 p/Share	2,000 Reduced 1.69%	116,071 Common Stock
Jan 07 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.67%	118,071 Common Stock
Dec 10 2024	SELL Open market or private sale	$369,672 $50.64 p/Share	7,300 Reduced 5.92%	116,071 Common Stock
Dec 10 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.12%	123,371 Common Stock
Dec 03 2024	SELL Payment of exercise price or tax liability	$104,462 $51.51 p/Share	2,028 Reduced 1.75%	114,071 Common Stock
Dec 03 2024	BUY Grant, award, or other acquisition	-	8,000 Added 6.35%	118,071 Common Stock
Nov 26 2024	SELL Open market or private sale	$366,095 $50.15 p/Share	7,300 Reduced 6.13%	111,878 Common Stock
Nov 26 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.26%	119,178 Common Stock
Nov 12 2024	SELL Open market or private sale	$370,880 $58.48 p/Share	6,342 Reduced 5.28%	113,878 Common Stock
Nov 12 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.22%	120,220 Common Stock
Oct 30 2024	SELL Open market or private sale	$379,016 $51.92 p/Share	7,300 Reduced 5.97%	114,920 Common Stock
Oct 30 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.16%	122,220 Common Stock
Oct 15 2024	SELL Open market or private sale	$395,587 $54.19 p/Share	7,300 Reduced 5.88%	116,920 Common Stock
Oct 15 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.09%	124,220 Common Stock
Oct 01 2024	SELL Open market or private sale	$380,330 $52.1 p/Share	7,300 Reduced 5.78%	118,920 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.09%	124,220 Common Stock
Sep 17 2024	SELL Open market or private sale	$414,348 $56.76 p/Share	7,300 Reduced 5.69%	120,920 Common Stock
Sep 17 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.97%	128,220 Common Stock
Sep 03 2024	SELL Open market or private sale	$420,961 $57.01 p/Share	7,384 Reduced 5.67%	122,920 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM